Alvotech will announce Q1 2026 financial results on May 6, followed by a webcast and Q&A on May 7.
Quiver AI Summary
Alvotech, a biotechnology company focused on developing and manufacturing biosimilar medicines, announced it will release its first quarter 2026 financial results on May 6, 2026, after the U.S. market closes. The company will host a webcast with a live Q&A session on May 7, 2026, at 08:00 ET. Participants can register for the webcast and Q&A in advance, and additional materials will be available on their investor website. Alvotech has five approved biosimilars and is developing nine more candidates to address various health conditions. The company aims to be a global leader in the biosimilars market through partnerships and a comprehensive in-house approach.
Potential Positives
- Announcement of first quarter 2026 financial results, indicating transparency and commitment to investor communication.
- Hosting a live Q&A webcast, providing an opportunity for direct engagement between the company and its investors.
- Details on the approval and marketing of five biosimilars demonstrate the company's established presence and success in the market.
- Highlighting a robust development pipeline with nine biosimilar candidates positions the company for future growth and expansion in various medical fields.
Potential Negatives
- Announcement of Q1 2026 financial results scheduled on May 6, 2026, may indicate potential concerns about prior performance, as delayed releases can sometimes reflect underlying issues.
- The live Q&A session following the financial results may expose vulnerable areas of the company's performance or strategy, leading to negative scrutiny from investors and analysts.
- The mention of a pipeline of nine biosimilar candidates suggests ongoing development challenges, as the lengthy and costly nature of biotechnology projects may raise questions about future profitability and market entry timelines.
FAQ
When will Alvotech release its Q1 2026 financial results?
Alvotech will release its Q1 2026 financial results on May 6, 2026, after the U.S. market close.
What time will the webcast for the financial results be held?
The webcast for the financial results will be held on May 7, 2026, at 08:00 ET.
How can I participate in the Q&A session?
To participate in the Q&A session, please register through the provided conference call registration link.
Where can I find the materials for the upcoming call?
Slides and other materials will be available on investors.alvotech.com/events before the call.
What types of medicines does Alvotech specialize in?
Alvotech specializes in the development and manufacture of biosimilar medicines for patients worldwide.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 29 institutional investors add shares of $ALVO stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OAKTREE CAPITAL MANAGEMENT LP removed 1,030,020 shares (-65.9%) from their portfolio in Q4 2025, for an estimated $5,284,002
- BLACKROCK, INC. added 369,925 shares (+45.9%) to their portfolio in Q4 2025, for an estimated $1,897,715
- MILLENNIUM MANAGEMENT LLC added 337,417 shares (+1707.7%) to their portfolio in Q4 2025, for an estimated $1,730,949
- NORGES BANK removed 180,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $923,400
- VANGUARD GROUP INC added 141,948 shares (+3.3%) to their portfolio in Q4 2025, for an estimated $728,193
- MARSHALL WACE, LLP removed 136,859 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $702,086
- ROYCE & ASSOCIATES LP removed 124,346 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $637,894
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALVO Analyst Ratings
Wall Street analysts have issued reports on $ALVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 11/18/2025
To track analyst ratings and price targets for $ALVO, check out Quiver Quantitative's $ALVO forecast page.
$ALVO Price Targets
Multiple analysts have issued price targets for $ALVO recently. We have seen 3 analysts offer price targets for $ALVO in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $4.0 on 03/24/2026
- Ashwani Verma from UBS set a target price of $6.0 on 03/24/2026
- Niall Alexander from Deutsche Bank set a target price of $8.0 on 11/04/2025
Full Release
REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close.
The Company will also host a webcast with a live Q&A on Thursday, May 7, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST).
- To listen to the webcast, please register here: Q1 2026 webcast registration
- To participate in the Q&A, please register here: Q1 2026 conference call registration
Slides and other material will be made available on investors.alvotech.com/events before the call.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
[email protected]
Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
[email protected]
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit
https://www.alvotech.com
. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram and YouTube .
